LIF Mediates Proinvasive Activation of Stromal Fibroblasts in Cancer

• LIF mediates fibroblast activation to promote invasive tumor microenvironment
• LIF signaling pathway supports TGF-β-induced tumorigenic ECM remodeling
• LIF expression correlates with poor clinical outcome in lung and head and neck tumors
• JAK1/2 Ruxolitinib inhibitor blocks tumor cells invasiveness in vivo

SummarySignaling crosstalk between tumor cells and fibroblasts confers proinvasive properties to the tumor microenvironment. Here, we identify leukemia inhibitory factor (LIF) as a tumor promoter that mediates proinvasive activation of stromal fibroblasts independent of alpha-smooth muscle actin (α-SMA) expression. We demonstrate that a pulse of transforming growth factor β (TGF-β) establishes stable proinvasive fibroblast activation by inducing LIF production in both fibroblasts and tumor cells. In fibroblasts, LIF mediates TGF-β-dependent actomyosin contractility and extracellular matrix remodeling, which results in collective carcinoma cell invasion in vitro and in vivo. Accordingly, carcinomas from multiple origins and melanomas display strong LIF upregulation, which correlates with dense collagen fiber organization, cancer cell collective invasion, and poor clinical outcome. Blockade of JAK activity by Ruxolitinib (JAK inhibitor) counteracts fibroblast-dependent carcinoma cell invasion in vitro and in vivo. These findings establish LIF as a proinvasive fibroblast producer independent of α-SMA and may open novel therapeutic perspectives for patients with aggressive primary tumors.

Graphical AbstractFigure optionsDownload as PowerPoint slide